See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Umashankar Singh
Indian Institute of Technology Gandhinagar
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8578-8201
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The antineoplastic agent Givinostat inhibits histone deacetylases. We present here our finding that the DNA-binding of human CGGBP1 is also inhibited by Givinostat. CGGBP1, a DNA-binding protein, is required for cancer cell proliferation. In our quest to exploit the potential anti-proliferative effects of CGGBP1 inhibition, we have developed a simple screening assay to identify chemical inhibitors of DNA-protein interactions. We have applied this screen for human CGGBP1 on a library of 1685 compounds and found that Givinostat is a direct inhibitor of CGGBP1-DNA interaction. The mechanism of action of Givinostat should thus extend beyond HDACs to include the inhibition of the myriad functions of CGGBP1 that depend on its binding to the DNA.
Keywords
Givinostat, CGGBP1, DNA-protein interaction, library screen
Figure 1
Figure 2
Figure 3
The full text of this article is available to read as a PDF.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 14 Oct, 2020
Editor assigned
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 09 Oct, 2020
Review #4 received
Received 02 Oct, 2020
Review #3 received
Received 02 Oct, 2020
Review #2 received
Received 15 Sep, 2020
Review #1 received
Received 09 Sep, 2020
Reviewer #4 agreed
On 07 Sep, 2020
Reviewer #3 agreed
On 04 Sep, 2020
Reviewer #1 agreed
On 02 Sep, 2020
Reviewer #2 agreed
On 02 Sep, 2020
Reviewers invited
Invitations sent on 01 Sep, 2020
Editor assigned
On 30 Aug, 2020
Submission checks complete
On 29 Aug, 2020
Editor invited
On 29 Aug, 2020
Version (no preprint)
Posted 30 Jan, 2020
Review #5 received
Received 28 Jul, 2020
Reviewer #5 agreed
On 08 Jul, 2020
Editorial decision: Major revision
On 19 Mar, 2020
Review #3 received
Received 17 Mar, 2020
Review #4 received
Received 16 Mar, 2020
Reviewer #4 agreed
On 26 Feb, 2020
Review #2 received
Received 25 Feb, 2020
Reviewer #3 agreed
On 24 Feb, 2020
Review #1 received
Received 20 Feb, 2020
Reviewer #2 agreed
On 14 Feb, 2020
Reviewer #1 agreed
On 06 Feb, 2020
Editor assigned
On 03 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Submission checks complete
On 02 Feb, 2020
Editor invited
On 02 Feb, 2020
This version was not preprinted
No comments provided
Editor assigned
On 28 Jan, 2020
Submission checks complete
On 27 Jan, 2020
Editor invited
On 27 Jan, 2020
Version 1
Posted 21 Jan, 2020
No comments provided
Editor assigned
On 22 Jan, 2020
Editorial decision: Revise before sending to peer reviewers
On 22 Jan, 2020
Submission checks complete
On 17 Jan, 2020
Editor invited
On 17 Jan, 2020
First submitted
On 14 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Umashankar Singh
Indian Institute of Technology Gandhinagar
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8578-8201
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 14 Oct, 2020
Editor assigned
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 09 Oct, 2020
Review #4 received
Received 02 Oct, 2020
Review #3 received
Received 02 Oct, 2020
Review #2 received
Received 15 Sep, 2020
Review #1 received
Received 09 Sep, 2020
Reviewer #4 agreed
On 07 Sep, 2020
Reviewer #3 agreed
On 04 Sep, 2020
Reviewer #1 agreed
On 02 Sep, 2020
Reviewer #2 agreed
On 02 Sep, 2020
Reviewers invited
Invitations sent on 01 Sep, 2020
Editor assigned
On 30 Aug, 2020
Submission checks complete
On 29 Aug, 2020
Editor invited
On 29 Aug, 2020
Version (no preprint)
Posted 30 Jan, 2020
Review #5 received
Received 28 Jul, 2020
Reviewer #5 agreed
On 08 Jul, 2020
Editorial decision: Major revision
On 19 Mar, 2020
Review #3 received
Received 17 Mar, 2020
Review #4 received
Received 16 Mar, 2020
Reviewer #4 agreed
On 26 Feb, 2020
Review #2 received
Received 25 Feb, 2020
Reviewer #3 agreed
On 24 Feb, 2020
Review #1 received
Received 20 Feb, 2020
Reviewer #2 agreed
On 14 Feb, 2020
Reviewer #1 agreed
On 06 Feb, 2020
Editor assigned
On 03 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Submission checks complete
On 02 Feb, 2020
Editor invited
On 02 Feb, 2020
This version was not preprinted
No comments provided
Editor assigned
On 28 Jan, 2020
Submission checks complete
On 27 Jan, 2020
Editor invited
On 27 Jan, 2020
Version 1
Posted 21 Jan, 2020
No comments provided
Editor assigned
On 22 Jan, 2020
Editorial decision: Revise before sending to peer reviewers
On 22 Jan, 2020
Submission checks complete
On 17 Jan, 2020
Editor invited
On 17 Jan, 2020
First submitted
On 14 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
The antineoplastic agent Givinostat inhibits histone deacetylases. We present here our finding that the DNA-binding of human CGGBP1 is also inhibited by Givinostat. CGGBP1, a DNA-binding protein, is required for cancer cell proliferation. In our quest to exploit the potential anti-proliferative effects of CGGBP1 inhibition, we have developed a simple screening assay to identify chemical inhibitors of DNA-protein interactions. We have applied this screen for human CGGBP1 on a library of 1685 compounds and found that Givinostat is a direct inhibitor of CGGBP1-DNA interaction. The mechanism of action of Givinostat should thus extend beyond HDACs to include the inhibition of the myriad functions of CGGBP1 that depend on its binding to the DNA.
Figure 1
Figure 2
Figure 3
The full text of this article is available to read as a PDF.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...